This company has been marked as potentially delisted and may not be actively trading. Presbia (LENS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock LENS vs. BVS, INFU, NSPR, TMDIF, PETV, HSAQ, RVP, GBS, BTCY, and CTCXShould you be buying Presbia stock or one of its competitors? The main competitors of Presbia include Bioventus (BVS), InfuSystem (INFU), InspireMD (NSPR), Titan Medical (TMDIF), PetVivo (PETV), Health Sciences Acquisitions Co. 2 (HSAQ), Retractable Technologies (RVP), GBS (GBS), Biotricity (BTCY), and Carmell (CTCX). These companies are all part of the "medical" sector. Presbia vs. Its Competitors Bioventus InfuSystem InspireMD Titan Medical PetVivo Health Sciences Acquisitions Co. 2 Retractable Technologies GBS Biotricity Carmell Presbia (NASDAQ:LENS) and Bioventus (NYSE:BVS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, dividends and risk. Is LENS or BVS more profitable? Bioventus has a net margin of -7.11% compared to Presbia's net margin of -36,604.35%. Bioventus' return on equity of 15.61% beat Presbia's return on equity.Company Net Margins Return on Equity Return on Assets Presbia-36,604.35% -414.02% -195.56% Bioventus -7.11%15.61%4.01% Do insiders & institutionals have more ownership in LENS or BVS? 16.4% of Presbia shares are held by institutional investors. Comparatively, 62.9% of Bioventus shares are held by institutional investors. 74.2% of Presbia shares are held by insiders. Comparatively, 33.0% of Bioventus shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility & risk, LENS or BVS? Presbia has a beta of 2.57, indicating that its share price is 157% more volatile than the S&P 500. Comparatively, Bioventus has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Which has preferable valuation and earnings, LENS or BVS? Presbia has higher earnings, but lower revenue than Bioventus. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPresbia$20K29,402.74-$8.41MN/AN/ABioventus$564.14M0.96-$156.23MN/AN/A Does the media refer more to LENS or BVS? In the previous week, Bioventus had 1 more articles in the media than Presbia. MarketBeat recorded 1 mentions for Bioventus and 0 mentions for Presbia. Bioventus' average media sentiment score of 1.85 beat Presbia's score of 0.00 indicating that Bioventus is being referred to more favorably in the news media. Company Overall Sentiment Presbia Neutral Bioventus Very Positive Do analysts rate LENS or BVS? Bioventus has a consensus target price of $13.75, suggesting a potential upside of 109.92%. Given Bioventus' stronger consensus rating and higher probable upside, analysts plainly believe Bioventus is more favorable than Presbia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Presbia 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Bioventus 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryBioventus beats Presbia on 10 of the 14 factors compared between the two stocks. Get Presbia News Delivered to You Automatically Sign up to receive the latest news and ratings for LENS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LENS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LENS vs. The Competition Export to ExcelMetricPresbiaSurgical & Medical Instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$588.06M$76.96M$6.06B$10.43BDividend YieldN/AN/A5.73%4.78%P/E RatioN/A9.7385.7927.08Price / Sales29,402.7440.02581.41185.05Price / CashN/A18.4125.7330.17Price / Book379.2217.1212.666.66Net Income-$8.41M-$27.88M$3.31B$276.03M Presbia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LENSPresbiaN/A$34.13-0.7%N/AN/A$588.06M$20K0.0024BVSBioventus3.2249 of 5 stars$6.70+0.8%$13.75+105.2%-46.3%$553.95M$564.14M-10.981,200INFUInfuSystem4.4174 of 5 stars$9.82-3.5%$13.50+37.5%+33.2%$200.18M$139.89M163.36410NSPRInspireMD2.8809 of 5 stars$2.44+0.8%$4.50+84.4%-10.1%$102.43M$7.07M-3.2750TMDIFTitan MedicalN/A$0.48-0.3%N/A+1,153.6%$54.74M$17.63M-0.3850PETVPetVivoN/A$1.30flatN/A+128.6%$38.07M$1.05M-2.8920Gap DownHSAQHealth Sciences Acquisitions Co. 2N/A$2.73-1.4%N/A-38.0%$30.61MN/A0.004RVPRetractable Technologies1.9971 of 5 stars$1.00+6.1%N/A+28.4%$29.88M$38.16M-1.85240Positive NewsGBSGBSN/A$1.14-2.6%N/A-28.2%$16.98MN/A-2.047Gap DownBTCYBiotricityN/A$0.51+6.3%N/A+136.3%$13.63M$12.06M-0.4740Gap UpCTCXCarmellN/A$0.60-19.4%N/A+73.2%$12.61M$32.84K0.0014Gap Down Related Companies and Tools Related Companies BVS Competitors INFU Competitors NSPR Competitors TMDIF Competitors PETV Competitors HSAQ Competitors RVP Competitors GBS Competitors BTCY Competitors CTCX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LENS) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Presbia PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Presbia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
